On Friday 1st June 2018

“On Friday 1^st June 2018, Merck/Pfizer announced that the current BAVENCIO (avelumab) metastatic Merkel cell carcinoma access program in Australia will be closed. Any patient request already approved on the access program was grandfathered on Friday, 1^st June, and will continue to receive BAVENCIO stock free of charge until unacceptable toxicity, progression or death.”